EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Colchicine has Dose‐Dependent Therapeutic Effects in a LPS ‐Induced Experimental Endotoxemia Model

Meliksah Demir iD, Ayse Yesim Gocmen, Esin Ozcelebi, Zuleyha Doganyigit, Aslı Okan Oflamaz, Alper Bektas Iskit iD

Pharmacology Research & Perspectives · 2026-04 · 14 (2)

DOI: 10.1002/prp2.70239 ↗

At a glance

Journal article in Pharmacology Research & Perspectives, published online on 2026-04-06. Written by Meliksah Demir and 5 co-authors. Institution: Department of Medical Pharmacology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. Major MEDLINE topics: Colchicine, Endotoxemia, Anti-Inflammatory Agents. 39 references. The full text is freely available (open access, CC BY 4.0). Funded by: Hacettepe Üniversitesi.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Colchicine is an ancient medication that has long been used for anti‐inflammatory properties. Because of unfavorable and toxic consequences of colchicine, selecting an appropriate dose is critical. The effects of three different doses (0.5, 1 or 5 mg/kg) of colchicine were evaluated. To stimulate systemic inflammation, we created an LPS‐induced experimental endotoxemia model with 1 mg/kg LPS intraperitoneal injection. Possible therapeutic effects of colchicine were investigated on cytokines, decreased mesenteric artery blood flow and histopathological damage scores. Treatment with 1 mg/kg colchicine reduced the pro‐inflammatory cytokines IL‐1β, TNF‐α, IL‐8, and IL‐17 to levels comparable to the control group and attenuated the damage caused by LPS in liver and spleen tissues. At a dose of 0.5 mg/kg, colchicine was not able to decrease cytokine levels to those of the control group. In contrast, administration of 5 mg/kg colchicine ameliorated mesenteric blood flow; however, this higher dose caused an increase in cytokine levels. Among three different colchicine doses, 1 mg/kg intraperitoneal dose significantly improved the inflammatory indices and may be considered a suitable option for anti‐inflammatory treatment.

Subjects

MeSH terms (MEDLINE)

ColchicineEndotoxemiaAnti-Inflammatory AgentsAnimalsLipopolysaccharidesMaleDose-Response Relationship, DrugCytokinesDisease Models, AnimalLiverMesenteric ArteriesRatsSpleenInjections, Intraperitoneal

Author keywords

LPS‐induced endotoxemiaanti‐inflammatory effectcolchicinemesenteric artery blood flowmultiple organ damage

Substances

ColchicineLipopolysaccharidesAnti-Inflammatory AgentsCytokines

Authors and institutions

  • Department of Medical Pharmacology, Hacettepe University, Faculty of Medicine, Ankara, Turkey.
  • Department of Histology and Embryology, Bozok University, Yozgat, Turkey.

ORCID profiles: Meliksah Demir, Alper Bektas Iskit

Funding

  • Hacettepe Üniversitesi

Cite

APA

Demir, M., Gocmen, A. Y., Ozcelebi, E., Doganyigit, Z., Oflamaz, A. O., & Iskit, A. B. (2026). Colchicine has Dose‐Dependent Therapeutic Effects in a LPS ‐Induced Experimental Endotoxemia Model. Pharmacology Research & Perspectives, 14(2). https://doi.org/10.1002/prp2.70239

Vancouver

Demir M, Gocmen AY, Ozcelebi E, Doganyigit Z, Oflamaz AO, Iskit AB. Colchicine has Dose‐Dependent Therapeutic Effects in a LPS ‐Induced Experimental Endotoxemia Model. Pharmacology Research & Perspectives. 2026;14(2). doi:10.1002/prp2.70239

BibTeX
@article{Demir2026,
  author = {Demir, Meliksah and Gocmen, Ayse Yesim and Ozcelebi, Esin and Doganyigit, Zuleyha and Oflamaz, Aslı Okan and Iskit, Alper Bektas},
  title = {Colchicine has Dose‐Dependent Therapeutic Effects in a LPS ‐Induced Experimental Endotoxemia Model},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  volume = {14},
  number = {2},
  doi = {10.1002/prp2.70239}
}
Start for free →